Victoria Muñoz, BS, Nursing Department, Quironsalud Bizkaia Hospital, Erandio, Spain.
Ander Pino, PhD, R&D Department, BTI Biotechnology Institute, Vitoria, Spain; R&D Department, University Institute of Regenerative Medicine and Oral Implantology (UIRMI), University of the Basque Country (UPV-EHU), Leioa, Spain.
Carmen Martinez, BS, Nursing Department, Quironsalud Bizkaia Hospital, Erandio, Spain.
Begoña Echevarria, BS, Nursing Department, Quironsalud Bizkaia Hospital, Erandio, Spain.
Varlan Lacramioara, BS, Nursing Department, Quironsalud Bizkaia Hospital, Erandio, Spain.
Eduardo Anitua, PhD, MD, DDS, R&D Department, BTI Biotechnology Institute, Vitoria, Spain, R&D Department, University Institute of Regenerative Medicine and Oral Implantology (UIRMI), University of the Basque Country (UPV-EHU), Leioa, Spain
Correspondence: Eduardo Anitua, PhD, MD, DDS, R&D Department, BTI Biotechnology Institute, Jacinto Quincoces 39, Vitoria, Spain ([email protected]).
Eduardo Anitua is the scientific director and Ander Pino is researcher at BTI Biotechnology Institute, the company that has developed the EndoretPRGF technology. Victoria Muñoz, Carmen Martinez, Begoña Echevarria, and Varlan Lacramioara declare no conflicts of interest.
